Advancing a class on top of statins
Investors & Media

Analyst Coverage

FirmAnalystE-Mail
Canaccord GenuityJohn Newman, Ph.D.jnewman@canaccordgenuity.com
H.C. Wainwright & Co., LLCEd Arceearce@hcwresearch.com
Jefferies LLCMatthew J. Andrewsmandrews1@jefferies.com
Laidlaw Capital MarketsFrancois Briseboisfbrisebois@laidlawltd.com
LifeSci Capital, LLCPatrick Dolezalpdolezal@lifescicapital.com
Piper Jaffray & Co.Charles Duncan, Ph.D.Charles.C.Duncan@pjc.com
Roth Capital PartnersYasmeen Rahimi, Ph.D.yrahim@roth.com
Gemphire Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Gemphire Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Gemphire Therapeutics, Inc. or its management. Gemphire Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.